Tech Company Financing Transactions

eGenesis Funding Round

eGenesis closed a $125 million Series C funding round on 3/3/2021. Investors included Alta Partners, Altium Capital and Arch Venture Partners.

Transaction Overview

Company Name
Announced On
3/3/2021
Transaction Type
Venture Equity
Amount
$125,000,000
Round
Series C
Investors

Alta Partners

Altium Capital

Arch Venture Partners (Steven Gillis)

Catalio Capital Management

Farallon Capital Management

Fresenius Medical Care

HBM Healthcare Investments

Invus

Irving Investors

Khosla Ventures

Leaps by Bayer

LifeSci Venture Partners

Monashee Investment Management

Osage Partners

Polaris Partners

Samsara BioCapital

Symbiosis

Wellington Partners

Proceeds Purpose
The company intends to use the funds to bring its lead programs in kidney and islet cell transplant into human proof-of-concept studies and continue to develop its proprietary gene-editing platform and scaling of GMP production.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
300 Technology Sq. 301
Cambridge, MA 02139
USA
Phone
Undisclosed
Email Address
Overview
eGenesis is a life sciences company focused on leveraging CRISPR technology to deliver safe and effective human transplantable cells, tissues and organs to the hundreds of thousands of patients worldwide who are in dire need.
Profile
eGenesis LinkedIn Company Profile
Social Media
eGenesis Company Twitter Account
Company News
eGenesis News
Facebook
eGenesis on Facebook
YouTube
eGenesis on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Paul Sekhri
  Paul Sekhri LinkedIn Profile  Paul Sekhri Twitter Account  Paul Sekhri News  Paul Sekhri on Facebook
Chief Operating Officer
Peter Hanson
  Peter Hanson LinkedIn Profile  Peter Hanson Twitter Account  Peter Hanson News  Peter Hanson on Facebook
VP - Bus. Development
Jennifer Bergheiser
  Jennifer Bergheiser LinkedIn Profile  Jennifer Bergheiser Twitter Account  Jennifer Bergheiser News  Jennifer Bergheiser on Facebook
VP - Bus. Development
Ariel Jasie
  Ariel Jasie LinkedIn Profile  Ariel Jasie Twitter Account  Ariel Jasie News  Ariel Jasie on Facebook
VP - Human Resources
Elizabeth Roberts
  Elizabeth Roberts LinkedIn Profile  Elizabeth Roberts Twitter Account  Elizabeth Roberts News  Elizabeth Roberts on Facebook
VP - R & D
Michael Curtis
  Michael Curtis LinkedIn Profile  Michael Curtis Twitter Account  Michael Curtis News  Michael Curtis on Facebook
VP - Regulatory Affairs
David Carmel
  David Carmel LinkedIn Profile  David Carmel Twitter Account  David Carmel News  David Carmel on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/3/2021: Presage Biosciences venture capital transaction
Next: 3/3/2021: Reperio Health venture capital transaction

 

Share this article

 


About Our VC Transactions Data

We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary